Seeking Alpha

Oncolytics Biotech (ONCY) soars 20.3% after saying its Reolysin treatment, in combination with...

Oncolytics Biotech (ONCY) soars 20.3% after saying its Reolysin treatment, in combination with carboplatin and paclitaxel, performed well in a Phase III trial of patients with head and neck cancer. Of 105 patients, 86% exhibited tumour stabilization or shrinkage vs 67% in the control group. The combo including Reolysin was also better at shrinking tumors than the two other treatments on their own. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|